Clinical Trials
200 trialsStem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
National Institutes of Health Clinical Center (CC)
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
National Institutes of Health Clinical Center (CC)
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
National Institutes of Health Clinical Center (CC)
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
National Institutes of Health Clinical Center (CC)
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Institutes of Health Clinical Center (CC)
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
National Institutes of Health Clinical Center (CC)
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
National Institutes of Health Clinical Center (CC)
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation for Patients With Cancers of the Blood
National Institutes of Health Clinical Center (CC)
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
National Institutes of Health Clinical Center (CC)
Improving Blood Stem Cell Collection and Transplant Procedures
National Institutes of Health Clinical Center (CC)
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
National Institutes of Health Clinical Center (CC)
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
National Institutes of Health Clinical Center (CC)
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
T-Cell Depletion in Unrelated Donor Marrow Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
Cord Blood Stem Cell Transplantation Study (COBLT)
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Research Network
National Heart, Lung, and Blood Institute (NHLBI)
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
National Institutes of Health Clinical Center (CC)
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
National Cancer Institute (NCI)
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Immunotoxin in Treating Patients With Leukemia or Lymphoma
National Cancer Institute (NCI)
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
National Cancer Institute (NCI)
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
National Institutes of Health Clinical Center (CC)